Sign in to use this feature.

Years

Between: -

Subjects

remove_circle_outline

Journals

Article Types

Countries / Regions

Search Results (1)

Search Parameters:
Authors = Robin J. Vigouroux

Order results
Result details
Results per page
Select all
Export citation of selected articles as:
16 pages, 397 KiB  
Review
In Vivo Applications of Single Chain Fv (Variable Domain) (scFv) Fragments
by Philippe P. Monnier, Robin J. Vigouroux and Nardos G. Tassew
Antibodies 2013, 2(2), 193-208; https://doi.org/10.3390/antib2020193 - 11 Apr 2013
Cited by 106 | Viewed by 39944
Abstract
Single chain variable domain (Fv) fragments (scFv) are powerful tools in research and clinical settings, owing to better pharmacokinetic properties compared to the parent monoclonal antibodies and the relative ease of producing them in large quantities, at low cost. Though they offer [...] Read more.
Single chain variable domain (Fv) fragments (scFv) are powerful tools in research and clinical settings, owing to better pharmacokinetic properties compared to the parent monoclonal antibodies and the relative ease of producing them in large quantities, at low cost. Though they offer several advantages, they suffer from lower binding affinity and rapid clearance from circulation, which limits their therapeutic potential. However, these fragments can be genetically modified to enhance desirable properties, such as multivalency, high target retention and slower blood clearance, and as such, a variety of scFv formats have been generated. ScFvs can be administered by systemic injection for diagnostic and therapeutic purposes. They can be expressed in vivo through viral vectors in instances where large infection rates and sustenance of high levels of the antibody is required. ScFvs have found applications as tools for in vivo loss-of-function studies and inactivation of specific protein domains, diagnostic imaging, tumor therapy and treatment for neurodegenerative and infectious diseases. This review will focus on their in vivo applications. Full article
(This article belongs to the Special Issue Single-Domain Antibody)
Show Figures

Figure 1

Back to TopTop